Compare NRT & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRT | CPIX |
|---|---|---|
| Founded | 1975 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.6M | 34.1M |
| IPO Year | N/A | 2009 |
| Metric | NRT | CPIX |
|---|---|---|
| Price | $6.35 | $4.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 40.5K | ★ 224.3K |
| Earning Date | 12-30-2025 | 11-04-2025 |
| Dividend Yield | ★ 12.90% | N/A |
| EPS Growth | ★ 24.05 | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | $6,184,173.00 | ★ $41,278,349.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.71 | ★ N/A |
| Revenue Growth | ★ 18.55 | 12.21 |
| 52 Week Low | $3.90 | $1.85 |
| 52 Week High | $6.95 | $7.25 |
| Indicator | NRT | CPIX |
|---|---|---|
| Relative Strength Index (RSI) | 52.89 | 73.82 |
| Support Level | $6.10 | $3.93 |
| Resistance Level | $6.51 | $4.59 |
| Average True Range (ATR) | 0.19 | 0.42 |
| MACD | -0.00 | 0.16 |
| Stochastic Oscillator | 43.75 | 80.28 |
North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.